Imperial College London Researchers Find Potential Way to Anti-Ageing and Prevent Cancer
A remarkable study conducted by scientists at the Medical Research Council Laboratory of Medical Science and Imperial College London has unveiled an incredible finding regarding the inhibition of a specific protein, interleukin 11 (IL-11), in mice. The study, published in the prestigious journal Nature, demonstrated that the targeted suppression of IL-11 resulted in a considerable extension of the mice’s healthy lifespan by nearly 25%.
The research involved the deletion of the IL-11 gene in mice, leading to a remarkable increase in their average lifespan by over 20%. Furthermore, the administration of an anti-IL-11 antibody to 75-week-old mice, equivalent to approximately 55 human years, resulted in a noteworthy median lifespan extension of 22.4% in males and 25% in females. Treated mice exhibited an average lifespan of 155 weeks, in stark contrast to the 120 weeks observed in untreated mice.
What’s particularly exciting is the broader impact of the anti-IL-11 treatment, which not only reduced cancer-related deaths in the mice but also mitigated the onset of numerous age-related diseases characterized by fibrosis, chronic inflammation, and metabolic decline. Profoundly, these interventions yielded minimal side effects, emphasizing their potential in promoting healthy aging.
Professor Stuart Cook, one of the co-corresponding authors of the study, emphasized the transformative implications of these findings. He noted substantial improvements in muscle strength and reduced muscle wasting in the treated mice, marking a departure from conventional life-extending interventions that often come with undesirable side effects.
The implications of this research extend to human health, with the potential for translating these findings to human subjects through clinical trials of anti-IL-11 treatments. This development holds promise for addressing age-related multimorbidity and frailty, representing crucial milestones in the quest for enhancing healthy aging.
Assistant Professor Anissa Widjaja, co-corresponding author of the study, shed light on the origins of this groundbreaking research, citing the discovery of age-related increases in IL-11 levels as a catalyst for further investigation. Uncovering the detrimental effects of heightened IL-11 levels, including inflammation and hindered organ regeneration, the research underscores the vital relevance of these findings to human health.
Previous characterizations of IL-11 as an evolutionary remnant in humans have been debunked by this research, as heightened IL-11 production past a certain age has been linked to various age-related ailments including chronic inflammation, fibrosis, metabolic disorders, muscle wasting, and frailty. These conditions, collectively termed as multimorbidity, pose significant challenges to global healthcare in the 21st century.
While these findings are undeniably promising, it’s imperative to underscore that the results pertain to mice and necessitate rigorous clinical assessments to establish the safety and efficacy of anti-IL-11 treatments in humans.
The discovery of the pivotal role of IL-11 in age-related ailments and the potential benefits of inhibiting this protein offer a compelling glimpse into the future of healthy aging interventions. This research sets the stage for paradigm-shifting advancements in the pursuit of mitigating age-related diseases and promoting prolonged, healthy lifespans.
– Rashmi Kumari
